- Conditions
- Breast Cancer
- Interventions
- pegfilgrastim, carboplatin, docetaxel, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 120
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 484
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Physical Inactivity, Overweight and Obesity
- Interventions
- Prevent T2, Move group-based classes, Fitness Membership, Mental Imagery, Move 1:1 Support
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Multiple Myeloma
- Interventions
- Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 6
- States / cities
- Duarte, California • Irvine, California • Denver, Colorado + 3 more
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Ravulizumab, Eculizumab
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Baltimore, Maryland + 2 more
- Conditions
- Frontotemporal Dementia
- Interventions
- LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone
- Biological · Drug
- Lead sponsor
- Prevail Therapeutics
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 4
- States / cities
- Maitland, Florida • Orlando, Florida • Burlington, Massachusetts + 1 more
- Conditions
- Malignant Brain Tumors
- Interventions
- Research Questionnaires, Palliative Care Team, Educational Information Session for Patients and Caregivers, Contact every 2 weeks, Follow-up Surgical Visit Session, Medical and/or Radiation Oncology Appointment Session
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Head and Neck Cancer
- Interventions
- Nivolumab, Cisplatin, Docetaxel, Intensity-modulated radiotherapy
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
- Conditions
- Resectable, Non-functioning Pituitary Adenoma
- Interventions
- Farletuzumab
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Myositis
- Interventions
- Nipocalimab, Placebo, Glucocorticoids
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
- Conditions
- Solid Tumors
- Interventions
- Avelumab
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Sacramento, California + 20 more
- Conditions
- Tree Nut Allergy
- Interventions
- Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 6 Years to 45 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- eftilagimod alfa, carboplatin plus paclitaxel, cisplatin or carboplatin + pemetrexed, pembrolizumab (KEYTRUDA®), Placebo
- Biological · Drug · Other
- Lead sponsor
- Immutep S.A.S.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Albuquerque, New Mexico • Austin, Texas
- Conditions
- Acute Coronary Syndrome, Physical Inactivity
- Interventions
- Tai chi + wearable
- Behavioral
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Andecaliximab, Nivolumab
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Daratumumab SC: daratumumab + rHuPH20
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more
- Conditions
- Liver Transplant Rejection
- Interventions
- CFZ533, Tacrolimus - MMF - corticosteroids
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Hereditary Hemorrhagic Telangiectasia
- Interventions
- Bevacizumab (Avastin®)
- Drug
- Lead sponsor
- Hanny Al-Samkari, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Epratuzumab
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 11 more
- Conditions
- Chronic Pain
- Interventions
- Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments
- Behavioral · Other · Procedure
- Lead sponsor
- Edward Via Virginia College of Osteopathic Medicine
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Auburn, Alabama
- Conditions
- Type 2 Diabetes
- Interventions
- telehealth-based clinical pharmacy intervention
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Leukemia
- Interventions
- mercaptopurine, methotrexate, tretinoin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 210
- States / cities
- Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
- Conditions
- Cardiomyopathies, Heart Failure
- Interventions
- Heart Rate Monitor Enhanced Treatment Optimization
- Device
- Lead sponsor
- Zoll Medical Corporation
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Cincinnati, Ohio • Kingwood, Texas • McKinney, Texas + 1 more